[go: up one dir, main page]

MX2009006891A - Anticuerpos cd44. - Google Patents

Anticuerpos cd44.

Info

Publication number
MX2009006891A
MX2009006891A MX2009006891A MX2009006891A MX2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A MX 2009006891 A MX2009006891 A MX 2009006891A
Authority
MX
Mexico
Prior art keywords
antibodies
relates
human
compositions
methods
Prior art date
Application number
MX2009006891A
Other languages
English (en)
Inventor
Haichun Huang
Vahe Bedian
Mohan Srinivasan
Kristopher Toy
Xu Xu
Erika Meaddough
Lan Yang
Advait V Badkar
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2009006891A publication Critical patent/MX2009006891A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La presente invención se relaciona con anticuerpos incluyendo anticuerpos humanos y porciones de unión a antígeno de los mismos que se unen a CD44, y que funcionan para inhibir CD44; la invención también se relaciona con inmunoglobulinas de cadena pesada y ligera derivadas de anticuerpos CD44 de humano y moléculas de ácido nucleico que codifican tales inmunoglobulinas; la presente invención también se relaciona con métodos para hacer anticuerpos CD44 de humano, composiciones que comprenden estos anticuerpos y métodos para usar los anticuerpos y composiciones o medicamentos para tratamiento.
MX2009006891A 2006-12-21 2007-12-20 Anticuerpos cd44. MX2009006891A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87610906P 2006-12-21 2006-12-21
PCT/US2007/025975 WO2008079246A2 (en) 2006-12-21 2007-12-20 Cd44 antibodies

Publications (1)

Publication Number Publication Date
MX2009006891A true MX2009006891A (es) 2009-08-28

Family

ID=39563077

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006891A MX2009006891A (es) 2006-12-21 2007-12-20 Anticuerpos cd44.

Country Status (16)

Country Link
US (1) US20100092484A1 (es)
EP (1) EP2102238A4 (es)
JP (1) JP2010512790A (es)
KR (1) KR20090094848A (es)
CN (1) CN101605812A (es)
AR (1) AR064456A1 (es)
AU (1) AU2007338844A1 (es)
BR (1) BRPI0720477A2 (es)
CA (1) CA2672916A1 (es)
CL (1) CL2007003807A1 (es)
MX (1) MX2009006891A (es)
PE (1) PE20081478A1 (es)
RU (1) RU2009128064A (es)
TW (1) TW200846365A (es)
UY (1) UY30776A1 (es)
WO (1) WO2008079246A2 (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8231872B2 (en) * 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
JP2012519710A (ja) * 2009-03-06 2012-08-30 アングストロム プハルマセウトイカルス インコーポレイテッド 細胞遊走を調整するための組成物、及び方法
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US10232039B2 (en) 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US20140335084A1 (en) * 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
MX350539B (es) 2012-02-13 2017-09-08 Bristol Myers Squibb Co Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
MX356698B (es) 2013-02-14 2018-06-11 Bristol Myers Squibb Co Compuestos de tubulisina, metodos para obtenerlos y uso.
EA201591652A1 (ru) 2013-03-06 2016-02-29 Мерримак Фармасьютикалз, Инк. ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
CN103288958B (zh) * 2013-03-22 2015-03-04 暨南大学 抗癌症干细胞特异性蛋白cd44的单链抗体及其应用
ES2769876T3 (es) 2013-08-14 2020-06-29 Univ Rice William M Derivados de uncialamicina, métodos de síntesis y su uso como agentes antitumorales
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
MX2016007533A (es) * 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
IL279606B (en) 2014-08-08 2022-08-01 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
BR112017010094A2 (pt) 2014-11-21 2018-02-06 Bristol-Myers Squibb Company anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
SG11201705636SA (en) 2015-01-26 2017-08-30 Lubris Llc Use of prg4 as an anti-inflammatory agent
EA201792221A1 (ru) 2015-04-07 2018-08-31 ЭЛЕКТОР ЭлЭлСи Антитела против сортилина и способы их применения
JP7497953B2 (ja) 2015-06-12 2024-06-11 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
CN108738323B (zh) 2015-10-06 2023-05-26 艾利妥 抗trem2抗体及其使用方法
AU2016343987B2 (en) 2015-10-29 2023-11-23 Alector Llc Anti-Siglec-9 antibodies and methods of use thereof
BR112018012524A2 (pt) 2015-12-21 2018-12-11 Bristol Myers Squibb Co anticorpos variantes para conjugação sítio-específica
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
WO2017196598A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
US10287291B2 (en) 2016-08-19 2019-05-14 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
WO2018107058A1 (en) 2016-12-09 2018-06-14 Alector Llc Anti-sirp-alpha antibodies and methods of use thereof
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
EP4098662A1 (en) 2017-05-25 2022-12-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3601358B1 (en) 2017-08-03 2023-05-17 Alector LLC Anti-trem2 antibodies and methods of use thereof
BR112019023789A2 (pt) 2017-08-03 2020-07-28 Alector Llc anticorpos anti-cd33 e métodos de uso dos mesmos
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
WO2019133512A1 (en) 2017-12-29 2019-07-04 Alector Llc Anti-tmem106b antibodies and methods of use thereof
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
CN112218893B (zh) 2018-05-25 2025-01-14 艾利妥 抗-sirpa抗体及其使用方法
IL312163B2 (en) 2018-05-29 2025-04-01 Bristol Myers Squibb Co Modified atomic groups that lend themselves to use in prodrugs and conjugates and methods for use and preparation
CA3100626A1 (en) 2018-06-08 2019-12-12 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2020006374A2 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
CA3104530A1 (en) 2018-07-09 2020-01-16 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
AU2019246837B2 (en) 2018-07-13 2024-03-21 Alector Llc Anti-Sortilin antibodies and methods of use thereof
US12258398B2 (en) 2018-07-27 2025-03-25 Alector Llc Anti-Siglec-5 antibodies and methods of use thereof
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
BR112021003016A2 (pt) 2018-08-31 2021-05-18 Alector Llc anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica
EP3867271A4 (en) * 2018-10-18 2022-08-03 Merck Sharp & Dohme Corp. FORMULATIONS OF ANTI-RSV ANTIBODIES AND METHODS OF USE
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
KR20210098488A (ko) 2018-11-30 2021-08-10 브리스톨-마이어스 스큅 컴퍼니 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
EP3894443A2 (en) 2018-12-12 2021-10-20 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102259298B1 (ko) * 2019-05-15 2021-05-31 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
BR112021025077A2 (pt) 2019-06-11 2022-05-03 Alector Llc Anticorpos anti-sortilina para uso em terapia
CN119954954A (zh) 2019-07-31 2025-05-09 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
US20240377413A1 (en) 2019-09-16 2024-11-14 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
WO2021119400A1 (en) 2019-12-12 2021-06-17 Alector Llc Methods of use of anti-cd33 antibodies
JP2023506465A (ja) 2019-12-13 2023-02-16 アレクトル エルエルシー 抗ＭｅｒＴＫ抗体及びその使用方法
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
EP4126937A1 (en) 2020-03-31 2023-02-08 Alector LLC Anti-mertk antibodies and methods of use thereof
BR112022019892A2 (pt) 2020-04-03 2022-12-13 Alector Llc Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo
EP4153192B8 (en) 2020-05-19 2024-09-04 Institut Curie Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
CN114057874B (zh) * 2020-07-31 2023-05-05 北京市神经外科研究所 抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途
KR20230117169A (ko) 2020-12-02 2023-08-07 알렉터 엘엘씨 항-소르틸린 항체의 사용 방법
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
US20240166738A1 (en) 2021-03-23 2024-05-23 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
WO2022243838A1 (en) 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
JP2024527262A (ja) 2021-06-16 2024-07-24 アレクトル エルエルシー 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
EP4419558A1 (en) 2021-10-19 2024-08-28 Alector LLC Anti-cd300lb antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
IL314896A (en) 2022-02-23 2024-10-01 Alector Llc Methods of use of anti-trem2 antibodies
MA71628A (fr) 2022-07-29 2025-05-30 Alector Llc Anticorps anti-gpnmb et leurs méthodes d'utilisation
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024093147A1 (zh) * 2022-10-31 2024-05-10 南京元迈细胞生物科技有限公司 一种特异性结合CD44的v5外显子的抗体及其用途
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
CN116554300B (zh) * 2023-04-27 2023-10-24 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543594A (en) * 1992-10-30 1994-05-24 Duke University An adhesion molecule
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20020055488A1 (en) * 2000-09-21 2002-05-09 Wessels Michael R. Prevention and treatment of streptococcal and staphylococcal infection
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
WO2005087264A1 (en) * 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury

Also Published As

Publication number Publication date
WO2008079246A3 (en) 2009-01-08
CA2672916A1 (en) 2008-07-03
WO2008079246A2 (en) 2008-07-03
AR064456A1 (es) 2009-04-01
RU2009128064A (ru) 2011-01-27
EP2102238A4 (en) 2010-09-01
EP2102238A2 (en) 2009-09-23
BRPI0720477A2 (pt) 2014-01-14
UY30776A1 (es) 2008-07-03
KR20090094848A (ko) 2009-09-08
CL2007003807A1 (es) 2008-05-09
CN101605812A (zh) 2009-12-16
PE20081478A1 (es) 2008-12-07
AU2007338844A1 (en) 2008-07-03
US20100092484A1 (en) 2010-04-15
TW200846365A (en) 2008-12-01
JP2010512790A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
MX2009006891A (es) Anticuerpos cd44.
NZ591471A (en) Antibodies to ccr2
PH12014501872A1 (en) P-cadherin antibodies
MX2010007406A (es) Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
TN2010000092A1 (en) Humanized cxcr5 antidodies, derivatives thereof and their uses
EP2511301A3 (en) Human antibodies to ERBB2
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
TW200724548A (en) Antibodies to myostatin
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
TW200709817A (en) Platform antibody compositions
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
EA200970874A1 (ru) Антитела против склеростина
WO2008060331A3 (en) Antibodies to sars coronavirus
WO2007024846A3 (en) Anit-il-23 antibiodies
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
WO2011004028A3 (en) Tlr3 binding agents
WO2009051957A3 (en) Antibodies to irem-1
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal